178 related articles for article (PubMed ID: 23264661)
1. Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
Takakuwa O; Oguri T; Maeno K; Yokoyama M; Hijikata H; Uemura T; Ozasa H; Ohkubo H; Miyazaki M; Niimi A
Am J Hosp Palliat Care; 2013 Nov; 30(7):726-9. PubMed ID: 23264661
[TBL] [Abstract][Full Text] [Related]
2. A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Koike K; Terui T; Nagasako T; Horiuchi I; Machino T; Kusakabe T; Hirayama Y; Mihara H; Yamakage M; Kato J; Nishisato T; Ishitani K
Support Care Cancer; 2016 Mar; 24(3):1053-9. PubMed ID: 26248654
[TBL] [Abstract][Full Text] [Related]
3. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy.
Ripamonti C; Fagnoni E; Campa T; Brunelli C; De Conno F
Support Care Cancer; 2006 May; 14(5):400-7. PubMed ID: 16485087
[TBL] [Abstract][Full Text] [Related]
4. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.
Radbruch L; Sabatowski R; Petzke F; Brunsch-Radbruch A; Grond S; Lehmann KA
Palliat Med; 2001 Jul; 15(4):309-21. PubMed ID: 12054148
[TBL] [Abstract][Full Text] [Related]
5. [A phase II clinical study of once-a-day fentanyl citrate patch in patients with cancer pain--switching from once-every-three-days fentanyl patch to once-a-day fentanyl citrate patch].
Miyazaki T; Namiki A; Ogawa S; Kitajima T; Masuda Y; Iwao Y; Uchida E; Iseki M; Matoba M; Hashizume T
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1747-52. PubMed ID: 20841939
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of analgesic effect and safety of fentanyl transdermal patch for cancer pain as the first line.
Hoya Y; Okamoto T; Yanaga K
Support Care Cancer; 2010 Jun; 18(6):761-4. PubMed ID: 20354734
[TBL] [Abstract][Full Text] [Related]
8. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
9. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids.
Mystakidou K; Befon S; Tsilika E; Dardoufas K; Georgaki S; Vlahos L
Oncology; 2002; 62(1):9-16. PubMed ID: 11810038
[TBL] [Abstract][Full Text] [Related]
10. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
11. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.
Kornick CA; Santiago-Palma J; Moryl N; Payne R; Obbens EA
Drug Saf; 2003; 26(13):951-73. PubMed ID: 14583070
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain.
Payne R
Semin Oncol; 1998 Jun; 25(3 Suppl 7):47-53. PubMed ID: 9671331
[TBL] [Abstract][Full Text] [Related]
13. Rapid switching between transdermal fentanyl and methadone in cancer patients.
Mercadante S; Ferrera P; Villari P; Casuccio A
J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
[TBL] [Abstract][Full Text] [Related]
14. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain.
Yamaguchi S; Uchida E; Terahara T; Okawa K; Hashimoto F; Tanaka Y
Clin Drug Investig; 2020 Nov; 40(11):1041-1052. PubMed ID: 32886320
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
Kress HG; Von der Laage D; Hoerauf KH; Nolte T; Heiskanen T; Petersen R; Lundorff L; Sabatowski R; Krenn H; Rosland JH; Saedder EA; Jensen NH
J Pain Symptom Manage; 2008 Sep; 36(3):268-79. PubMed ID: 18538974
[TBL] [Abstract][Full Text] [Related]
17. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.
Jeal W; Benfield P
Drugs; 1997 Jan; 53(1):109-38. PubMed ID: 9010652
[TBL] [Abstract][Full Text] [Related]
18. Improved cancer pain treatment using combined fentanyl-TTS and tramadol.
Marinangeli F; Ciccozzi A; Aloisio L; Colangeli A; Paladini A; Bajocco C; Coaccioli S; Varrassi G
Pain Pract; 2007 Dec; 7(4):307-12. PubMed ID: 17986161
[TBL] [Abstract][Full Text] [Related]
19. Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer.
Zhu H; Xiao H; Lu G; Fang S
Biomed Res Int; 2022; 2022():9722458. PubMed ID: 35924273
[TBL] [Abstract][Full Text] [Related]
20. Initial dose cascade of TTS fentanyl with proper adjuvant medications in cancer pain.
Baik SW; Kim KH; Kim YC; Lee SC; Kim DK; Jung JE
J Korean Med Sci; 2003 Oct; 18(5):733-7. PubMed ID: 14555829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
